Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Myeloid Leukemia
Vion Pharmaceuticals Submits New Drug Application for Onrigin(TM)
March 6th, 2009
VION PHARMACEUTICALS, INC. (BULLETIN BOARD: VION) announced that it has filed a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for its lead oncology therapeutic Onrigin (laromustine) Injection as a single agent for remission induction treatment for patients sixty years of age or older with de novo poor-risk acute myeloid leukemia (AML). The Company has requested a priority review for the application and, if granted, Onrigin could receive approval for this indication in the second half of 2009. Alan Kessman, Chief Executive Officer, commented, "This NDA filing is a significant milestone for Vion and for the Onrigin clinical development...
Source: Health Business Week (2009-03-06)
|
